Simvastatin and Ezetimibe is indicated for:
Population group: only adults (18 years old or older)
Ezetimibe/simvastatin combination is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS), either previously treated with a statin or not.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Ezetimibe/simvastatin combination is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g. low-density lipoprotein [LDL] apheresis).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Ezetimibe/simvastatin combination is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate:
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Simvastatin and Ezetimibe is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
